CIK 0001750019
TCRR TCR2 THERAPEUTICS INC.
Insider trading from SEC Form 4. Last filing Feb 14, 2024.
In brief
TCR2 THERAPEUTICS INC. (TCRR) has 55 SEC Form 4 filings on file from 18 insiders, the latest filed on Feb 14, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
22 open-market trades have been scored at TCRR. The newest: Kevin C Tang (10% owner) bought $86k of stock on May 25, 2023, filed May 30, 2023, scored 31 (weak). The largest of the 22 shown: Kevin C Tang (10% owner) bought $548k on May 3, 2023, scored 39 (weak). 2 insiders sold within 14 days of each other around May 22, 2023.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
18
with a Form 4 at this company
Signals
Open-market buys and sells at TCR2 THERAPEUTICS INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Kevin C Tang owner buy | $86k 50,000 shares | +1% | - | |
| 36Weak | Mpm Asset Management LLC owner sell | $132k 70,170 shares | -19% | - | |
| 39Weak | Ansbert Gadicke director, owner sell | $132k 70,170 shares | -19% | - | |
| 31Weak | Kevin C Tang owner buy | $88k 44,948 shares | +1% | - | |
| 33Weak | Kevin C Tang owner buy | $164k 83,988 shares | +2% | - | |
| 39Weak | Kevin C Tang owner buy | $548k 289,577 shares | +7% | - | |
| 15Weak | Alfonso Quintas Cardama Chief Medical Officer sell | $15k 13,799 shares | -11% | - | |
| 15Weak | Angela Justice Chief People Officer sell | $9,448 8,620 shares | -15% | - | |
| 31Weak | Garry E Menzel President and CEO sell | $35k 31,938 shares | -19% | - | |
| 15Weak | Peter Olagunju Chief Technical Officer sell | $5,299 4,830 shares | -17% | - | |
| 10Weak | Alfonso Quintas Cardama Chief Medical Officer sell | $10k 7,942 shares | -6% | - | |
| 10Weak | Angela Justice Chief People Officer sell | $6,301 4,968 shares | -8% | - | |
| 20Weak | Garry E Menzel President and CEO sell | $23k 18,425 shares | -10% | - | |
| 10Weak | Peter Olagunju Chief Technical Officer sell | $3,533 2,788 shares | -9% | - | |
| 10Weak | Alfonso Quintas Cardama Chief Medical Officer sell | $10k 7,464 shares | -5% | - | |
| 10Weak | Angela Justice Chief People Officer sell | $6,310 4,663 shares | -7% | - | |
| 30Weak | Garry E Menzel President and CEO sell | $32k 23,416 shares | -11% | - | |
| 10Weak | Peter Olagunju Chief Technical Officer sell | $3,531 2,618 shares | -8% | - | |
| 0Weak | Alfonso Quintas Cardama Chief Medical Officer sell | $5,054 3,636 shares | -3% | - | |
| 0Weak | Angela Justice Chief People Officer sell | $3,162 2,273 shares | -3% | - | |
| 5Weak | Garry E Menzel President & CEO sell | $12k 8,408 shares | -4% | - | |
| 0Weak | Peter Olagunju Chief Technical Officer sell | $1,766 1,273 shares | -4% | - |
Transactions
The newest 50 of 195 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2023 | Kevin C Tang owner | JOther Common Stockindirect: By LP | -4,394,800 | - | - | 0 | Feb 14, 2024 |
| Jun 1, 2023 | UBS Oncology Impact Fund L.P. owner | JOther Common Stock | -3,370,982 | $0.00 | $0 | 0 | Jun 5, 2023 |
| Jun 1, 2023 | MPM BioVentures 2014, L.P. owner | JOther Common Stockindirect: See Footnote | -4,158,964 | $0.00 | $0 | 0 | Jun 5, 2023 |
| Jun 1, 2023 | MPM SunStates Fund, L.P. owner | JOther Common Stockindirect: See Footnote | -4,158,964 | $0.00 | $0 | 0 | Jun 5, 2023 |
| Jun 1, 2023 | Ansbert Gadicke director, owner | JOther Common Stockindirect: See Footnote | -304,001 | $0.00 | $0 | 0 | Jun 5, 2023 |
| Jun 1, 2023 | Ansbert Gadicke director, owner | JOther Common Stockindirect: See Footnote | -3,854,963 | $0.00 | $0 | 0 | Jun 5, 2023 |
| Jun 1, 2023 | Ansbert Gadicke director, owner | JOther Common Stockindirect: See Footnote | -3,370,982 | $0.00 | $0 | 0 | Jun 5, 2023 |
| Jun 1, 2023 | Axel Hoos director | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Alfonso Quintas Cardama Chief Medical Officer | DDisposition to issuer Common Stock | -109,459 | - | - | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Angela Justice Chief People Officer | DDisposition to issuer Common Stock | -48,745 | - | - | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Eric Sullivan Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,820 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Garry E Menzel President and CEO | DDisposition to issuer Common Stockindirect: See Footnote | -132,729 | - | - | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Andrew R Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Neil W Gibson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Stephen W Webster director | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Shawn Tomasello director | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Peter Olagunju Chief Operating Officer | DDisposition to issuer Common Stock | -24,092 | - | - | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Rosemary Harrison Chief Business & Strategy | DDisposition to issuer Stock Option (Right to Buy)derivative | -76,930 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Priti Hegde director | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Priti Hegde director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Axel Hoos director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,596 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Angela Justice Chief People Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -78,499 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Alfonso Quintas Cardama Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -70,649 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Shawn Tomasello director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Eric Sullivan Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -250,000 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Stephen W Webster director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Peter Olagunju Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -98,124 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Garry E Menzel President and CEO | DDisposition to issuer Common Stockindirect: See Footnote | -132,730 | - | - | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Neil W Gibson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,270 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Rosemary Harrison Chief Business & Strategy | DDisposition to issuer Restricted Stock Unitderivative | -12,822 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Andrew R Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Priti Hegde director | DDisposition to issuer Stock Option (Right to Buy)derivative | -24,968 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Axel Hoos director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Neil W Gibson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Andrew R Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Angela Justice Chief People Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -76,500 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Stephen W Webster director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Alfonso Quintas Cardama Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -31,582 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Garry E Menzel President and CEO | DDisposition to issuer Common Stock | -138,871 | - | - | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Shawn Tomasello director | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,191 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Eric Sullivan Chief Financial Officer | DDisposition to issuer Restricted Stock Unitderivative | -6,804 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Peter Olagunju Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Rosemary Harrison Chief Business & Strategy | DDisposition to issuer Stock Option (Right to Buy)derivative | -191,102 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Axel Hoos director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Angela Justice Chief People Officer | DDisposition to issuer Restricted Stock Unitderivative | -13,083 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Alfonso Quintas Cardama Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,346 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Andrew R Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Stephen W Webster director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,482 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Neil W Gibson director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | Peter Olagunju Chief Operating Officer | DDisposition to issuer Restricted Stock Unitderivative | -16,354 | $0.00 | $0 | 0 | Jun 1, 2023 |
50 of 195 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Andrew R Allendirector, ceo, president, officer
- Alfonso Quintas CardamaChief Medical Officer
- Ansbert Gadickeowner, other, director
- Neil W Gibsondirector
- Rosemary HarrisonChief Business & Strategy
- Priti Hegdedirector
- Axel Hoosdirector
- Angela JusticeChief People Officer
- Mpm Asset Management LLCowner, other
- MPM BioVentures 2014, L.P.owner, other
- MPM SunStates Fund, L.P.owner
- Garry E MenzelPresident and CEO
- Peter OlagunjuChief Operating Officer
- Eric SullivanChief Financial Officer
- Kevin C Tangdirector, ceo, officer, owner
- Shawn Tomasellodirector
- UBS Oncology Impact Fund L.P.owner, other
- Stephen W Websterdirector
Questions about TCRR
Answered from the filings on this page, as of the latest one.
Are insiders buying TCRR?
No. In the last 90 days no insider at TCR2 THERAPEUTICS INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TCRR on the open market?
Kevin C Tang (10% owner) bought $86k of TCRR on May 25, 2023 and filed the Form 4 on May 30, 2023. InsiderTell scored 31 (weak).
How many insiders file Form 4 at TCR2 THERAPEUTICS INC.?
18 people have filed a Form 4 at TCR2 THERAPEUTICS INC., among them Andrew R Allen (director, CEO and president), Alfonso Quintas Cardama (Chief Medical Officer), Ansbert Gadicke (10% owner and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.